| Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031 A Sarr, J Bré, IH Um, TH Chan, P Mullen, DJ Harrison, PA Reynolds Scientific Reports 9 (1), 7643, 2019 | 13 | 2019 |
| Heparanase-1 is upregulated by hepatitis C virus and favors its replication C Gallard, N Lebsir, H Khursheed, E Reungoat, ML Plissonnier, J Bré, ... Journal of hepatology 77 (1), 29-41, 2022 | 8 | 2022 |
| The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agent J Bré, AL Dickson, OJ Read, Y Zhang, FG McKissock, P Mullen, P Tang, ... Cancer Chemotherapy and Pharmacology 91 (5), 401-412, 2023 | 6 | 2023 |
| NUC-1031 overcomes resistance associated with gemcitabine in cancer patients J Bré, A Sarr, P Mullen, IH Um, SP Blagden, PA Reynolds, DJ Harrison Cancer Research 78 (13_Supplement), 1855-1855, 2018 | 2 | 2018 |
| Defining the mode of action of cisplatin combined with a phosphoramidate modification of gemcitabine D Patel, AL Dickson, GM Zickuhr, IH Um, OJ Read, CM Czekster, P Mullen, ... | | 2024 |
| NUC-3373 is a potent TS inhibitor and induces DNA damage in NSCLC cancer cells regardless of histological subtype B Kaghazchi, AL Dickson, G Zickuhr, DJ Harrison, J Bré European Journal of Cancer 174, S66, 2022 | | 2022 |
| NUC-3373 induces DAMPs release from NSCLC cells potentiating a favourable immunogenic microenvironment B Kaghazchi, IH Um, J Bré, DJ Harrison, OJ Read European Journal of Cancer 174, S46, 2022 | | 2022 |
| NUC-3373 targets the DNA-directed pathway more effectively than 5-FU J Bré, AL Dickson, OJ Read, Y Zhang, CM Czekster, DJ Harrison Cancer Research 82 (12_Supplement), 1835-1835, 2022 | | 2022 |
| NUC-3373 potentiates immune-mediated cytotoxicity of CRC cells OJ Read, J Bré, DJ Harrison Cancer Research 82 (12_Supplement), 1113-1113, 2022 | | 2022 |
| Abstract P025: NUC-3373 is a more potent inhibitor of thymidylate synthase than 5-FU and reduces generation of toxic metabolites J Bré, AL Dickson, OJ Read, Y Zhang, P Mullen, CM Czekster, ... Molecular Cancer Therapeutics 20 (12_Supplement), P025-P025, 2021 | | 2021 |
| NUC-3373 induced DAMPs release in CRC cells promotes natural killer cell activation OJ Read, DJ Harrison, J Bré Cancer Research 81 (13_Supplement), 1655-1655, 2021 | | 2021 |
| NUC-1031 causes incorporation of fluorinated deoxycytidine into DNA, inducing persistent damage in biliary tract cancer cells D Patel, AL Dickson, OJ Read, CM Czekster, EA Ghazaly, DJ Harrison, ... Cancer Research 81 (13_Supplement), 1003-1003, 2021 | | 2021 |
| NUC-1031 causes release of DAMPs and upregulates PD-L1 expression in lung cancer cells J Bré, OJ Read, DJ Harrison Cancer Research 80 (16_Supplement), 1840-1840, 2020 | | 2020 |
| Exploration of the pharmacodynamic profile of Acelarin, a novel ProTide drug, in an in vitro model of ovarian cancer J Bré University of St Andrews, 2019 | | 2019 |
| Anti-cancer activity in patients with advanced ovarian and biliary tract cancers treated with NUC-1031 and platinum agents SP Blagden, J Bré, P Mullen, C Gnanaranjan, EA Ghazaly, ... Journal of Clinical Oncology 37 (15), 2019 | | 2019 |
| Genome-scale CRISPR/Cas9 screen identifies factors required for sensitivity to pyrimidine nucleoside analogs A Sarr, J Bré, P Mullen, S Blagden, IH Um, DJ Harrison, PA Reynolds Cancer Research 78 (13_Supplement), 572-572, 2018 | | 2018 |
| Supplementary information Heparanase is upregulated by HCV and favors its replication C Gallard, N Lebsir, H Khursheed, E Reungoat, ML Plissonnier, J Bré, ... | | |
